Childhood-Onset Neurodegeneration With Progressive Microcephaly (CONPM) due to a DTYMK Homozygous Pathogenic Variant: Outlining the Phenotype of an Ultra-Rare Disease
- PMID: 40696808
- DOI: 10.1002/ajmg.a.64187
Childhood-Onset Neurodegeneration With Progressive Microcephaly (CONPM) due to a DTYMK Homozygous Pathogenic Variant: Outlining the Phenotype of an Ultra-Rare Disease
Abstract
Childhood-onset neurodegeneration with progressive microcephaly (CONPM) is a rare autosomal recessive disorder caused by pathogenic variants in the DTYMK gene. This ultra-rare condition is characterized by progressive neurological regression, epilepsy, severe microcephaly, and global cerebral atrophy. Only four cases have been reported in the literature to date. This paper's objective is to describe the fifth globally reported case of CONPM and the first documented in a Mexican patient, confirmed through whole-exome sequencing (WES), and to compare findings with previously reported cases. Clinical evaluation, neuroimaging studies, and genetic analysis using WES followed by Sanger sequencing were performed. Clinical and genetic data were analyzed in the context of existing literature on CONPM. A 2-year-old male with progressive neurodevelopmental regression presented with severe microcephaly, epilepsy, hypertonia, and cortical and cerebellar atrophy. Genetic analysis identified a homozygous missense variant in DTYMK (NM_012145.4:c.242C>T; p.Pro81Leu). This variant is predicted to disrupt dTMP phosphorylation, a key step in the maintenance of dTTP pools required for genomic stability and neural function. This case expands the known phenotypic and genotypic spectrum of CONPM and underscores the importance of considering DTYMK variants in cases of childhood neurodegeneration with microcephaly. Further functional studies are needed to elucidate the mechanisms linking DTYMK dysfunction to neurodegeneration.
© 2025 Wiley Periodicals LLC.
References
-
- Bonilla, E., D. C. De Vivo, S. Shanske, and S. DiMauro. 2006. “Clinical Spectrum of Mitochondrial DNA Depletion due to Mutations in the Thymidine Kinase 2 Gene.” Archives of Neurology 63, no. 8: 1122–1126.
-
- El‐Hattab, A. W., and F. Scaglia. 2013. “Mitochondrial DNA Depletion Syndromes: Review and Updates of Genetic Basis, Manifestations, and Therapeutic Options.” Neurotherapeutics 10, no. 2: 186–198.
-
- Frisk, J. H., J. M. Vanoevelen, J. Bierau, G. Pejler, S. Eriksson, and L. Wang. 2021. “Biochemical Characterizations of Human TMPK Mutations Identified in Patients With Severe Microcephaly: Single Amino Acid Substitutions Impair Dimerization and Abolish Their Catalytic Activity.” ACS Omega 6, no. 49: 33943–33952.
-
- González‐Vioque, E., J. Torres‐Torronteras, A. L. Andreu, and R. Martí. 2011. “Limited dCTP Availability Accounts for Mitochondrial DNA Depletion in Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE).” PLoS Genetics 7, no. 3: e1002035.
-
- Lam, C. W., W. L. Yeung, T. K. Ling, K. C. Wong, and C. Y. Law. 2019. “Deoxythymidylate Kinase, DTYMK, Is a Novel Gene for Mitochondrial DNA Depletion Syndrome.” Clinica Chimica Acta 496: 93–99.
Publication types
LinkOut - more resources
Full Text Sources